0
Startups & Venture·November 4, 2026·1 min read

bit.bio raises $25M Series D as demand for its human cell models grows

Share

Demand for programmable human cell models is a bet that in vitro biology will keep pulling work away from animal models and slow, bespoke wet labs. If you’re in drug discovery or tools, assume partners will expect tighter integration with standardized cell platforms over the next 12–24 months.

Startups & Venture

Sentra, which helps restrict and monitor data access for AI agents, raised a $150M Series C led by Capital One Ventures, taking its total funding to $250M+

Security money is now following agents, not just data lakes—$150M into Sentra is a bet that controlling what AI can touch becomes its own category, not a feature. If you’re piloting agents on production data, you need a real access-control and observability story this quarter, not a Jira ticket for “later hardening.”

Startups & Venture

AI sales automation startup Nooks secures a $500M commitment from General Catalyst's CVF, which will take a share of the returns generated by the capital

A $500M dedicated commitment into Nooks’ sales and marketing engine is a bet that AI-assisted outbound can be financed like an asset class, not just a budget line. If you run a sales-heavy org, expect your board to start asking why your go-to-market isn’t underwritten or instrumented at this level of capital efficiency.